SCHEMBL2004444

SCHEMBL2004444

COc1nccc(C(=O)O)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 7/20 0.42
KDM4C Q9H3R0 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
ASPH Q12797 2/20 0.41
KDM8 Q8N371 2/20 0.41
IKBKB O14920 1/20 0.40
KDM5A P29375 3/20 0.39
KDM5B Q9UGL1 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29949269 1.00 LMNA (0.46) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL26709065 0.86 KDM4E (0.49) TDP1ALDH1A1KDM4EL3MBTL1IKBKB
SCHEMBL7854250 0.84 KDM4E (0.51) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL9042332 0.83 L3MBTL1 (0.43) TDP1ALDH1A1KDM4EKDM4CKMT2A
SCHEMBL19330179 0.80 KDM4E (0.59) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL31270462 0.80 LMNA (0.47) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL21818791 0.80 LMNA (0.47) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL16475154 0.80 LMNA (0.47) LMNATDP1POLBALDH1A1KDM4E
SCHEMBL7840880 0.79 NUDT1 (0.49) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL23177321 0.79 LMNA (0.46) LMNATDP1POLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104679-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 WO disclosed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20250320204-A1 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC (US) 2025-10-16 US disclosed
EP-4615454-A1 SOS1 INHIBITORS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-09-17 EP disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 EP disclosed
CN-118908957-A Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-11-08 CN disclosed
US-12077539-B2 Imidazole and triazole KRAS inhibitors INCYTE CORPORATION (US) 2024-09-03 US disclosed
EP-3976597-B1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-08-28 EP disclosed
CN-114222737-B Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-07-26 CN disclosed
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-06-20 US disclosed
US-9701677-B2 Fused pyrimidine compounds GILEAD SCIENCES, INC. (US) 2017-07-11 US disclosed
US-20160251347-A1 FUSED PYRIMIDINE COMPOUNDS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) 2016-09-01 US disclosed
US-20160251347-A1 FUSED PYRIMIDINE COMPOUNDS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) 2016-09-01 US disclosed
US-20160251347-A1 FUSED PYRIMIDINE COMPOUNDS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) 2016-09-01 US disclosed
WO-2016105532-A1 FUSED PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2016-06-30 WO disclosed
WO-2016105532-A1 FUSED PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2016-06-30 WO disclosed
WO-2015155306-A1 NEW TRPA1 ANTAGONISTS ALMIRALL, S.A. (ES) 2015-10-15 WO disclosed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077539-B2 Imidazole and triazole KRAS inhibitors KRAS, NRAS, HRAS LMNA 3265/4885TDP1 1212/4885POLB 737/4885
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 LMNA 4491/4885TDP1 2669/4885POLB 4357/4885
US-20250320204-A1 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, PDE7A LMNA 3730/4885TDP1 102/4885POLB 908/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG LMNA 3314/4885TDP1 3147/4885POLB 2829/4885
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, IKBKE LMNA 2913/4885TDP1 2446/4885POLB 989/4885
US-20160251347-A1 FUSED PYRIMIDINE COMPOUNDS TYMS, DPYD, TYMP LMNA 1837/4885TDP1 78/4885POLB 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.